Skip to main content
. 2021 Aug 24;4:1001. doi: 10.1038/s42003-021-02526-y

Fig. 3. SW620 tumour spheroids response at day 7 following various schedules of SN38 and AZD0156 delivered in microfluidic Ibidi chip.

Fig. 3

a Brightfield microscope images of SW620 tumour spheroids at day 0 and 7 days following different treatment schedules with SN38 and AZD0156: A Untreated day 0; B SN38 monotherapy; C SN38 + AZD0156 1/7; D SN38 + AZD0156 7/7; E SN38 + AZD0156 3/7 (24 h gap); F SN38 + AZD0156 3/7 (72 h gap); G Untreated day 7; b Spheroids were imaged in situ in the chip at day 7 and their volumes calculated from average radius deducted from min/max Feret. c Spheroids were recovered from the chip at day 7 and their viability measured by CellTiterGlo assay. n ≥ 5 per condition from two independent experiments. Box-plots show median (centre line); box limits are 25th to 75th percentile; whiskers represent min and max values. Statistical analysis using 1-way ANOVA, Tukey’s multiple comparisons, CI = 95%, ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.1.